4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
News, Articles of Incorporation, Bylaws
Lease Termination Agreement with GNS South Tower, LP Executed
Material Contracts, Reg. FD
Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets
Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Implements Workforce Reduction of 70%
Kezar Life Sciences Repays $6.3 Million Under Loan Agreement
Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS
Post-Effective Amendment to Registration Statement
Amended Schedule 14D-9 Solicitation/Recommendation Statement
Amended Tender Offer Statement by Third Party